Highlights Mabwell (Shanghai) Bioscience Co., Ltd.

Equities

688062

CNE100005RD2

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
31.64 ^CNY	-1.16%		-3.42%	-3.21%

May. 24	Mabwell Announces 9MW2821 Clinical Data	CI
May. 13	Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Mabwell Announces 9MW2821 Clinical Data	May. 24	CI
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer	May. 13	CI
Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821	May. 07	CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Mabwell Announces MAIWEIJIAN, First Approved Biosimilar of Denosumab in China	Apr. 08	CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
Mabwell Shanghai Bioscience Unit Gets Nod in China for Denosumab as Bone Tumor Treatment	Apr. 04	MT
Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting	Mar. 19	CI
Mabwell Scraps Licensing Deal With Yangtze River Pharma	Feb. 27	MT
Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology	Feb. 21	CI
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711	Feb. 20	CI
National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA	Dec. 19	CI
Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial	Dec. 11	CI
Mabwell Shanghai Bioscience Gets Nod to Trial Urothelial Cancer Drug	Dec. 08	MT
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs	23-10-23	CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-18	CI
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor	23-09-28	CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Mabwell Bioscience Co., Ltd. Announces the U.S. FDA approval of 9MW3811 for IND	23-06-15	CI
Mabwell Shanghai Bioscience Gets Nod to Trial 9MW3811 Injection	23-05-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mabwell (Shanghai) Bioscience Co., Ltd.

Equities

688062

CNE100005RD2

Highlights

Filters